Ethyl trans-4-oxo-2-butenoate CAS 2960-66-9
Fumaraldehydic Acid Ethyl Ester;
(2E)-4-Oxobut-2-enoic Acid Ethyl Ester;
Osteoporosis is a bone disease characterized by low bone mass and structural degradation of bone tissue. Osteoporosis treatments currently used clinically, such as estrogen, selective estrogen modulators, calcitonin, and bisphosphonates, are mainly beneficial to reduce bone resorption; there are also some treatments such as fluoride and Parathyroid hormone can increase bone formation. Anti-bone resorption therapy is very effective in treating osteoporosis, even if it usually does not induce the formation of new bone.
Anti-bone resorption therapy is very effective in treating osteoporosis, even if it usually does not induce the formation of new bone. To date, bisphosphonates are still the most widely used anti-bone resorption drugs.They are all synthetic analogs of endogenous mineral deposition inhibitor pyrophosphate, which can inhibit bone resorption and increase bone mineral density ( BMD) can effectively treat osteoporosis, Paget's disease and tumor-related bone disease, but its mechanism of action is not clear.
Ethyl Trans-4-oxo-2-butenoate CAS 2960-66-9 is the mainly intermediate of Minodronic acid.
Minodronic acid: Osteoporosis
Administration of minophosphonic acid can effectively inhibit bone loss and bone microstructure degradation caused by inflammation. This product can significantly inhibit the increase in the number of osteoclasts and bone resorption caused by arthritis and the acceleration of bone turnover, and can inhibit the reticulation Bone loss and maintenance of bone microstructure.